IBI363 clinical trials
IBI363 is named as an intervention in 17 current clinical trials in our China, USA and Australia registers. 10 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Innovent Biologics (Suzhou) Co. Ltd (10). The most-studied condition is Melanoma.
Patient leaflets for IBI363
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of IBI363
17 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with IBI363
17 conditionsAll 17 conditions
| Condition (as registered) | Trials |
|---|---|
| Melanoma | 3 |
| Colorectal Cancer | 2 |
| IBI363 + Chemotherapy | 2 |
| Advanced Malignancies | 2 |
| Non-small Cell Lung Cancer | 1 |
| Renal Cell Cancer | 1 |
| Solid Tumors or Lymphoma | 1 |
| Unresectable Stage III Non-small Cell Lung Cancer | 1 |
| Carcinoma, Non-Small-Cell Lung Cancer (NSCLC) | 1 |
| Resectable Stage II-III Non-small Cell Lung Cancer | 1 |
| Advan'ce'd | 1 |
| Advanced | 1 |
| EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer | 1 |
| Advanced Solid Tumor | 1 |
| Non Small Cell Lung Cancer | 1 |
| Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer | 1 |
| Solid Malignancies or Lymphomas | 1 |
Sponsors
lead sponsor per trialBy country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 15 | 9 |
| Clinical trials in USA | 1 | 1 |
| Clinical trials in Australia | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about IBI363 trials
How many clinical trials are testing IBI363?
17 current trials in our China, USA and Australia registers name IBI363 (also registered as IBI325) as a drug or biological intervention, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.
Are IBI363 trials recruiting patients?
Yes. 10 of the 17 trials are recruiting: 9 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors IBI363 clinical trials?
Innovent Biologics (Suzhou) Co. Ltd (10), Shanghai Pulmonary Hospital, Shanghai, China (2), Xiangdong Cheng (1) and Zhejiang Cancer Hospital (1), among 7 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how IBI363 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how IBI363 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists IBI363 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.